Cargando…
Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
Management of Graves’ orbitopathy remains an important therapeutic challenge. Current therapeutic modalities are unsatisfactory in about one third of patients. Rituximab is a monoclonal antibody against CD20 antigen that is expressed in mature and immature B cells. Early experience with rituximab su...
Autores principales: | Şimşek, Tülay, Yıldırım, Nilgün, Efe, Belgin, Kebapçı, Nur |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Galenos Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5282540/ https://www.ncbi.nlm.nih.gov/pubmed/28182165 http://dx.doi.org/10.4274/tjo.26780 |
Ejemplares similares
-
Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives
por: Supronik, Jakub, et al.
Publicado: (2022) -
Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
por: Campi, Irene, et al.
Publicado: (2022) -
Zirconium-89 labelled rituximab PET-CT imaging of Graves’ orbitopathy
por: de Keizer, Bart, et al.
Publicado: (2019) -
Graves' Orbitopathy
por: Hiromatsu, Yuji, et al.
Publicado: (2015) -
Acute Corneal Hydrops in Keratoconus Patients with Graves’ Orbitopathy
por: Dogan, Aysun Sanal, et al.
Publicado: (2021)